For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase ( ...

Tenaya plans to present data from its pediatric non-interventional natural history study, known as MyClimb, in the second ...

Edgewise Therapeutics, Inc. , a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief Executive Officer ...

Background and aims Hypertrophic cardiomyopathy (HCM) has various aetiologies, including genetic conditions like Fabry ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

A study reveals that a personalized approach, considering age, sex and size, improves the diagnosis of hypertrophic ...

Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural differences in sex and body size.

Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural differences in sex and body size, according to a new study led by UCL ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

Dr. Lakshmi Sundar emphasizes the importance of exercise for health while addressing the risk of sudden cardiac death in ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...